Logo
x

Search

Subscribe Now

Wet AMD

Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 2021

Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 202...

  • November 15, 2021
Outlook Reports Results of ONS-5010 / Lytenava (bevacizumab-vikg) in P-III NORSE TWO Trial for the Treatment of Wet AMD

Outlook Reports Results of ONS-5010 / Lytenava (bevacizumab-vikg) in P-III NORSE TWO Trial for the Treatment of Wet AMD

  • August 4, 2021
Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD

Regenxbio Reports the Initiation of First Pivotal Program for RGX-314 to Treat Wet AMD

  • January 6, 2021
Novartis' Beovu (brolucizumab) Receives EMA's Approval for its Safety Label Update to Treat Wet Age-Related Macular Degeneration

Novartis' Beovu (brolucizumab) Receives EMA's Approval for its Safety Label Update to Treat Wet Age-Related Macular Degeneration

  • September 15, 2020
Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD

Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD

  • September 9, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.